Payment overview · 2025
General Payments
$359.57
18 reported records · 11 companies
Healthcare provider profile · identity verified
Shanon L Custer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAYS, KS · NPI 1902870637
Verified facts
What the public records show
CMS Open Payments records show Shanon L Custer, MD received $359.57 in general payments during 2025 across 18 reported records.
Amgen Inc. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.31 | 19.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.29 | 12.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.16 | 10.9% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.28 | 9.0% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.59 | 8.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $30.82 | 8.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.44 | 8.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.20 | 7.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.37 | 5.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.68 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.43 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $359.57 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.29 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $32.28 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $31.59 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $30.82 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 691 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 600 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 591 | 110 |
| Escitalopram Oxalate | Escitalopram Oxalate | 431 | 68 |
| Potassium Chloride | Potassium Chloride | 423 | 77 |
| Gabapentin | Gabapentin | 417 | 67 |
| Losartan Potassium | Losartan Potassium | 400 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 90 |
| Tramadol Hcl | Tramadol Hcl | 306 | 57 |
| Furosemide | Furosemide | 301 | 70 |
| Simvastatin | Simvastatin | 292 | 69 |
| Omeprazole | Omeprazole | 274 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 53 |
| Lisinopril | Lisinopril | 258 | 57 |
| Eliquis | Apixaban | 248 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 56 |
| Montelukast Sodium | Montelukast Sodium | 209 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 41 |
| Metformin Hcl Er | Metformin Hcl | 186 | 41 |
| Celecoxib | Celecoxib | 182 | 37 |
| Carvedilol | Carvedilol | 176 | 35 |
| Mirtazapine | Mirtazapine | 165 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 29 |
| Donepezil Hcl | Donepezil Hcl | 162 | 26 |
| Allopurinol | Allopurinol | 157 | 30 |
| Xarelto | Rivaroxaban | 136 | 14 |
| Bumetanide | Bumetanide | 129 | 20 |
| Famotidine | Famotidine | 128 | 21 |
| Warfarin Sodium | Warfarin Sodium | 122 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 24 |
| Buspirone Hcl | Buspirone Hcl | 118 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 23 |
| Metformin Hcl | Metformin Hcl | 114 | 29 |
| Myrbetriq | Mirabegron | 114 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 113 | 17 |
| Spironolactone | Spironolactone | 110 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 20 |
| Trazodone Hcl | Trazodone Hcl | 104 | 16 |
| Memantine Hcl | Memantine Hcl | 102 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 11 |
| Lorazepam | Lorazepam | 88 | 21 |
| Mounjaro | Tirzepatide | 87 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 21 |
| Ozempic | Semaglutide | 83 | 11 |
| Januvia | Sitagliptin Phosphate | 78 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 14 |
| Meloxicam | Meloxicam | 74 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 13 |
| Alendronate Sodium | Alendronate Sodium | 72 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 13 |
| Colestipol Hcl | Colestipol Hcl | 71 | 14 |
| Glimepiride | Glimepiride | 70 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | 16 |
| Jardiance | Empagliflozin | 67 | suppressed |
| Pregabalin | Pregabalin | 67 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 12 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 59 | 12 |
| Sertraline Hcl | Sertraline Hcl | 58 | suppressed |
| Alprazolam | Alprazolam | 57 | suppressed |
| Fentanyl | Fentanyl | 56 | suppressed |
| Prednisone | Prednisone | 56 | 44 |
| Baclofen | Baclofen | 50 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 50 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 50 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 49 | suppressed |
| Atenolol | Atenolol | 48 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Lansoprazole | Lansoprazole | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 11 |
| Glipizide | Glipizide | 46 | suppressed |
| Sucralfate | Sucralfate | 46 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 27 |
| Primidone | Primidone | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 30 |
| Meclizine Hcl | Meclizine Hcl | 41 | 13 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Metolazone | Metolazone | 40 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 21 |
| Methenamine Hippurate | Methenamine Hippurate | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Premarin | Estrogens, Conjugated | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nystatin | Nystatin | 26 | 21 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Linzess | Linaclotide | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Terbutaline Sulfate | Terbutaline Sulfate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $359.57 · 18 records | Amgen Inc. | AREXVY, CeQur Simplicity, EVENITY, Empaveli, GEMTESA, GIVLAARI, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Omnipod, REPATHA, TAVNEOS, TRELEGY ELLIPTA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error